Table 1.
Demographic and clinical characteristics of the 405 patients enrolled in the study.
| Parameters | Results |
|---|---|
| Median age, years (IQR) | 68 (56–78) |
| Males/females | 251/154 |
| Male/female ratio | 1.6 |
| Median BMI (kg/m2) (IQR) | 25.7 (23.4–31.0) |
| BMI (kg/m2), n (%) 1 | |
| - Normal (18.5–24.9) | 125 (45.0) |
| - Overweight (25.0–29.9) | 71 (25.5) |
| - Grade 1 obesity (30.0–34.9) | 51 (18.3) |
| - Grade 2 obesity (35–39.9) | 23 (8.3) |
| - Grade 3 obesity (>40) | 8 (2.9) |
| Associated comorbidities, n (%) 2 | |
| - Hypertension | 184 (56.8) |
| - Dyslipidemia | 107 (33.0) |
| - Cardiovascular disease | 96 (29.6) |
| - Diabetes | 70 (21.6) |
| - Chronic lung disease | 38 (11.7) |
| - Cancer | 33 (10.2) |
| - Chronic kidney disease | 31 (9.6) |
| - <3 comorbidities | 241 (74.4) |
| - >3 comorbidities | 83 (25.6) |
| COVID-19 severity, n (%) | |
| - PaO2/FiO2 3 | |
| > 200–300 | 76 (18.8) |
| 100–200 | 281 (69.4) |
| < 100 | 48 (11.8) |
| - Hospital department | |
| Low intensity | 281 (69.4) |
| Intermediate/high intensity | 124 (30.6) |
| Concomitant therapies, n (%) | |
| - Antiviral agents 4 | 84 (20.7) |
| - Antibiotics | 264 (65.2) |
| - Hydroxychloroquine | 52 (12.8) |
| - Steroids | 332 (82.0) |
| - Anticoagulants 5 | 388 (95.8) |
| Median interval between symptoms onset and CCP therapy, days (IQR) |
7.5 (5–12) |
| ABO blood type, n (%) | |
| - O | 158 (39.0) |
| - A | 188 (46.4) |
| - B | 44 (10.9) |
| - AB | 15 (3.7) |
Abbreviations: IQR, interquartile range; BMI, body mass index; CCP, COVID-19 convalescent plasma. 1 Data available on 278 patients. 2 Data available on 324 patients. 3 Measured before convalescent plasma transfusion. 4 Protease inhibitors and remdesivir. 5 Low molecular weight heparin.